LIF is making research and development of Sildenafil syrup and tablets.
Syldenafil syrup is an orphan medicine used to treat Pulmonary Arterial Hypertension (PAH)* of the newborn. This is developed with the
School of Sciences Biochemical
On the other hand LIF is working on the development of Sildenafil tablets used to treat erectile dysfunction.
* PAH is a rare disease with an incidence of about 2-3 per million per year and a prevalence of about 15 per million. Adult females are almost three times as likely to present with PAH as adult males. The presentation of IPAH within children is more evenly split along gender lines. (N. Rudarakanchana, R C Trembath, N. W. Morrel. New insights into the pathogenesis and treatment of primary pulmonary hypertension)